Advertisement
CCCC vs FDMT
Which Stock Would AI Choose? C4 Therapeutics (CCCC) vs. 4D Molecular Therapeutics (FDMT) Stock Comparison
Key Takeaways
- Different clinical stages: CCCC is a clinical-stage oncology company advancing targeted protein degraders, while FDMT is a late-stage genetic medicines company with a lead gene therapy in Phase 3 trials.
- Distinct catalysts: CCCC's value hinges on cemsidomide data for multiple myeloma, while FDMT's hinges on 4D-150 readouts in retinal diseases.
- Balance-sheet contrast: FDMT holds a larger cash position (roughly $458 million) than CCCC (about $300 million), with both guiding runway into 2028.
- Relative positioning: Both are pre-revenue, unprofitable biotechs, but FDMT carries a larger market capitalization and higher share price, reflecting its later development stage.
- For deeper context on each name, explore CCCC Major News and CCCC Today's Price Move, as well as FDMT Major News and FDMT Today's Price Move.
- To see how automated strategies are positioning across names like these, explore Trending AI Robots.
Introduction
Investors evaluating small- and mid-cap biotechnology stocks often weigh pipeline catalysts, cash runway, and development-stage risk. CCCC (C4 Therapeutics) and FDMT (4D Molecular Therapeutics) offer a useful contrast: one is a clinical-stage oncology company built around targeted protein degradation, while the other is a late-stage genetic medicines developer focused on retinal diseases. This stock comparison is relevant for growth-oriented and event-driven investors assessing relative performance, market positioning, and the trade-offs between earlier-stage upside potential and later-stage, data-dependent risk.
CCCC Overview and Recent Performance
C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degraders (TPDs), a class of small-molecule medicines designed to degrade disease-causing proteins. Its lead candidate, cemsidomide, is an oral IKZF1/3 degrader being studied in multiple myeloma across several trials, including the Phase 2 MOMENTUM study.
In recent market activity, CCCC has traded near the middle of a 52-week range that spans roughly $1.69 to $5.17, with shares having gained substantially earlier in the year before giving back some of that momentum. Sentiment has been supported by a new collaboration with Roche focused on degrader-antibody conjugates (DACs), which included a $20 million upfront payment, and by analyst initiations with Buy ratings. The company reported about $300 million in cash as of mid-2026 and has guided that its runway extends to the end of 2028. Net losses have narrowed modestly, though revenue remains small and collaboration-dependent. Key upcoming catalysts, including Phase 1b updates and later Phase 2 data, remain several quarters away.
FDMT Overview and Recent Performance
4D Molecular Therapeutics is a late-stage biotechnology company developing genetic medicines. Its lead candidate, 4D-150, is an intravitreal gene therapy designed to provide multi-year, sustained delivery of anti-VEGF biologics for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), with a separate program, 4D-710, targeting cystic fibrosis.
In recent weeks, FDMT has traded in a 52-week range of approximately $6.96 to $16.93, with its market capitalization around $700 million. The company completed enrollment and randomization in its North American 4FRONT-1 Phase 3 trial of 4D-150, with global enrollment completion expected in the second half of 2026 and topline data anticipated in 2027. An expanded partnership with Otsuka provided an $85 million upfront payment, and the company reported roughly $458 million in cash, with guidance for funding into the second half of 2028. Net losses widened as research and development spending increased, reflecting the cost of running late-stage trials.
Trending AI Robots
For traders who prefer a data-driven, systematic approach to names like CCCC and FDMT, Tickeron maintains a library of hundreds of AI trading bots covering thousands of tickers. Because each bot uses its own trading style, strategy, timeframe, and risk profile, only a select subset is well suited to prevailing market conditions at any given moment. Those are the strategies surfaced in the curated Trending AI Robots section, which highlights the bots whose recent performance and statistics currently stand out. Exploring this page can help investors identify automated approaches aligned with their own objectives.
Head-to-Head Comparison
The two companies differ most clearly in therapeutic focus and development maturity. C4 Therapeutics operates in oncology, pursuing a platform-driven approach to protein degradation where the science is still being validated clinically; its lead asset is in Phase 1b/2, with pivotal data years away. 4D Molecular Therapeutics, by contrast, has already advanced its lead gene therapy into Phase 3, placing it closer to potential regulatory milestones but also concentrating risk on a smaller number of later-stage readouts.
Financial positioning also diverges. FDMT's roughly $458 million cash balance and larger market capitalization reflect its later stage and the backing of the Otsuka collaboration. CCCC's smaller cash position and lower share price reflect its earlier clinical stage and more dilute, collaboration-driven revenue base. On sentiment, both stocks carry Strong Buy consensus ratings among analysts, though CCCC has recently attracted new coverage while FDMT has seen some price-target adjustments. Risk factors include binary clinical data, heavy cash burn, and, for CCCC specifically, longer timelines to value inflection.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely view FDMT as the more stable, catalyst-rich candidate in the current environment. Its later-stage pipeline, larger cash cushion, and nearer-term data milestones generally translate into more consistent trend signals and clearer market positioning than an earlier-stage, longer-horizon name. CCCC may carry higher potential upside given its valuation and emerging platform, but its dependence on more distant readouts introduces greater variability in momentum. These conclusions are probabilistic, not definitive, and depend on how each stock's trend and volatility metrics evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CCCC is a Hold and FDMT is a Buy.
CCCC's Stochastic Oscillator sits in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CCCC's RSI Oscillator exited the oversold zone, 31 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +6.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCCC advanced for three days, in 194 of 236 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CCCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCCC as a result. In 81 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CCCC turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 41 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CCCC moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for CCCC moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCCC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CCCC entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.542) is normal, around the industry mean (3.498). P/E Ratio (-3.407) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.989) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. CCCC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FDMT's RSI Indicator ascending out of oversold territory
The RSI Indicator for FDMT moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 26 of the 28 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 57 cases where FDMT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on FDMT as a result. In 75 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for FDMT just turned positive on October 29, 2026. Looking at past instances where FDMT's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +10.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where FDMT advanced for three days, in 217 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
FDMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day moving average for FDMT crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FDMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FDMT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.660) is normal, around the industry mean (3.498). P/E Ratio (-4.658) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (9.662) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. FDMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FDMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CCCC | FDMT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 15 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 29 Undervalued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 58 | 48 | |
P/E GROWTH RATING 1..100 | 28 | 59 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FDMT's Valuation (25) in the null industry is in the same range as CCCC (29). This means that FDMT’s stock grew similarly to CCCC’s over the last 12 months.
FDMT's Profit vs Risk Rating (100) in the null industry is in the same range as CCCC (100). This means that FDMT’s stock grew similarly to CCCC’s over the last 12 months.
FDMT's SMR Rating (97) in the null industry is in the same range as CCCC (98). This means that FDMT’s stock grew similarly to CCCC’s over the last 12 months.
FDMT's Price Growth Rating (48) in the null industry is in the same range as CCCC (58). This means that FDMT’s stock grew similarly to CCCC’s over the last 12 months.
CCCC's P/E Growth Rating (28) in the null industry is in the same range as FDMT (59). This means that CCCC’s stock grew similarly to FDMT’s over the last 12 months.
| CCCC | FDMT | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 79% | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | 3 days ago 82% | 3 days ago 83% |
| Declines ODDS (%) | 7 days ago 90% | 10 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 68% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CCCC’s FA Score shows that 2 FA rating(s) are green while FDMT’s FA Score has 1 green FA rating(s).
- CCCC’s FA Score: 2 green, 3 red.
- FDMT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CCCC’s TA Score shows that 4 TA indicator(s) are bullish while FDMT’s TA Score has 6 bullish TA indicator(s).
- CCCC’s TA Score: 4 bullish, 6 bearish.
- FDMT’s TA Score: 6 bullish, 3 bearish.
Price Growth
CCCC (@Biotechnology) experienced а -6.54% price change this week, while FDMT (@Biotechnology) price change was +4.27% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
CCCC is expected to report earnings on Feb 25, 2027.
FDMT is expected to report earnings on Feb 26, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CCCC and
Correlation & Price change
A.I.dvisor indicates that over the last year, CCCC has been loosely correlated with NTLA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CCCC jumps, then NTLA could also see price increases.
| Ticker / NAME | Correlation To CCCC | 1D Price Change % | ||
|---|---|---|---|---|
| CCCC | 100% | -4.76% | ||
| NTLA - CCCC | 44% Loosely correlated | -7.76% | ||
| RCKT - CCCC | 43% Loosely correlated | -3.16% | ||
| SVRA - CCCC | 43% Loosely correlated | -2.57% | ||
| SLDB - CCCC | 42% Loosely correlated | +2.14% | ||
| FDMT - CCCC | 42% Loosely correlated | -0.16% | ||
More | ||||
FDMT and
Correlation & Price change
A.I.dvisor indicates that over the last year, FDMT has been loosely correlated with KYTX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if FDMT jumps, then KYTX could also see price increases.
| Ticker / NAME | Correlation To FDMT | 1D Price Change % | ||
|---|---|---|---|---|
| FDMT | 100% | -0.16% | ||
| KYTX - FDMT | 59% Loosely correlated | -1.74% | ||
| RCKT - FDMT | 55% Loosely correlated | -3.16% | ||
| PRME - FDMT | 54% Loosely correlated | -9.30% | ||
| EDIT - FDMT | 54% Loosely correlated | -8.91% | ||
| SLDB - FDMT | 53% Loosely correlated | +2.14% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| POLYX.X | 0.030438 | 0.000260 | +0.86% |
| Polymesh cryptocurrency | |||
| LDO.X | 0.326156 | 0.000258 | +0.08% |
| Lido DAO cryptocurrency | |||
| ERN.X | 0.984076 | -0.000156 | -0.02% |
| Ethos Reserve Note cryptocurrency | |||
| ARPA.X | 0.009070 | -0.000088 | -0.96% |
| ARPA cryptocurrency | |||
| PIVX.X | 0.021085 | -0.002522 | -10.68% |
| PIVX cryptocurrency | |||